Last reviewed · How we verify
0.2% Ropivacaine
At a glance
| Generic name | 0.2% Ropivacaine |
|---|---|
| Also known as | Experimental drug, 0,2% ropivacaine, PENG block with 0.2% ropivacaine, Ropin, Naropin |
| Sponsor | Northwestern University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Patient-Titrated Automated Intermittent Boluses of Local Anesthetic vs. a Continuous Infusion Via a Perineural Catheter for Postoperative Analgesia (PHASE4)
- Paravertebral Block for Mastectomy With Immediate Reconstruction (NA)
- Erector Spinae Plane Block for Acute Low Back Pain (NA)
- Local Infiltration Analgesia Versus Quadruple Nerve Blocks in Total Knee Arthroplasty. (NA)
- The Effect of Dexamethasone Administration Route in PENG Block for Pediatric Hip Surgery (PHASE4)
- Diaphragm-Sparing Regional Anesthesia Techniques for Shoulder Surgery (NA)
- PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults (NA)
- PENG Block Optimization: Volume and Dexamethasone Effects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.2% Ropivacaine CI brief — competitive landscape report
- 0.2% Ropivacaine updates RSS · CI watch RSS
- Northwestern University portfolio CI